BIOGENERA SpA specialises in creating DNA-based, patient-specific biotech medicines for treating serious pathologies.
Founded in 2008 and headquartered in Bologna, this highly innovative SME has a multidisciplinary team of researchers and draws support from numerous University partnerships (particularly the University of Bologna) and other companies in the biotechnology/pharmaceutical sector.
Thanks to their exclusive MyGeneraTM platform, BIOGENERA can rapidly identify and develop new patient-specific medicines based on blocking, in a highly selective way, mutated and pathological genes. Tackling the problem at its source, rather than treating the symptoms, opens the doors for curing a range of serious pathologies such as tumours, genetic, cardiovascular, neurodegenerative and infective diseases.
in 2009 META was the first investor in Biogenera, together with a number of Business Angels.